Looking back on research tools & consumables stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Danaher (NYSE:DHR) and its p...
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...
Diversified science and technology company Danaher (NYSE:DHR) fell short of the market’s revenue expectations in Q1 CY2026 as sales rose 3.7% year on year to...
Diversified science and technology company Danaher (NYSE:DHR) fell short of the market’s revenue expectations in Q1 CY2026 as sales rose 3.7% year on year to...
Diversified science and technology company Danaher (NYSE:DHR) will be reporting results this Tuesday before market open. Here’s what to expect. Danaher met a...
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have realized stron...
Today marks a definitive turning point for Hologic, Inc. (NASDAQ: HOLX). As the company prepares to finalize its $18.3 billion acquisition by private equity giants Blackstone and TPG, it stands as a testament to the resilience and strategic focus required in the modern medtech landscape. Known globally as a pioneer in women’s health, Hologic has [...]
Although the S&P 500 is down 2.8% over the past six months, Danaher’s stock price has fallen further to $190.75, losing shareholders 9.3% of their capital. T...
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including Danaher (NYSE:DHR) and its peers. Th...
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...
As of March 10, 2026, the United States financial markets are witnessing an unprecedented explosion in Mergers and Acquisitions (M&A) that has caught even the most optimistic analysts by surprise. Driven by a historic surge in private equity confidence—now sitting at a six-year high of 86%—the deal-making
As the first quarter of 2026 draws to a close, the healthcare and life sciences sectors are grappling with a "new normal" defined by capital conservatism and geopolitical friction. Industry bellwethers, once buoyed by post-pandemic expansion and aggressive R&D spending, are now issuing sober forecast revisions that reflect a
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
WALTHAM, MA — In a market defined by shifting geopolitical alliances and a renewed "flight to quality," Thermo Fisher Scientific (NYSE:TMO) has once again asserted its dominance as the bedrock of the life sciences sector. Reporting its fourth-quarter 2025 results on January 29, 2026, the company delivered a robust earnings
On January 15, 2026, the medical technology sector witnessed its most significant seismic shift in years as Boston Scientific Corporation (NYSE:BSX) announced a definitive agreement to acquire Penumbra, Inc. (NYSE:PEN) for an enterprise value of approximately $14.5 billion. This transaction, structured as a mix of 73% cash
In a move that has sent shockwaves through the medical technology sector, Danaher Corporation (NYSE: DHR) announced on February 17, 2026, that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ: MASI) for $180.00 per share in an all-cash transaction. The deal, valued at approximately $9.
